News about Clinical Trials

SOFIE Biosciences doses first patient in Phase III FAPI-PRO trial for pancreatic cancer imaging

SOFIE Biosciences has dosed the first patient in its Phase III FAPI-PRO trial evaluating 18F-FAPI-74 PET/CT for detecting metastatic pancreatic ductal adenocarcinoma, with 18 sites planned across 24 months.

Clinical Trials | 13/02/2026 | By News Bureau |  196

Centivax Begins Phase-I Trial of Universal Flu Vaccine

Unlike conventional seasonal influenza vaccines, which must be reformulated annually to attempt to match predicted circulating strains, Centi-Flu 01 is designed to focus both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate, and are shared across strains and distance subtypes.

Clinical Trials | 13/02/2026 | By News Bureau

Annovis Secures DSMB Nod to Advance Phase-III Buntanetap Trial in Alzheimer's

During the open session, Annovis presented an overview of the trial status, including enrollment progress, adverse events and study timelines. In the closed session, attended exclusively by DSMB voting members to ensure full objectivity and by an unblinded reporting statistician, unmasked safety data were reviewed.

Clinical Trials | 13/02/2026 | By News Bureau |  128

ArkBio Receives US FDA IND Clearance for AK3280 in Idiopathic Pulmonary Fibrosis

FDA clears ArkBio’s IND application for AK3280, enabling a Phase II proof-of-concept trial in the US to evaluate the novel anti-fibrotic therapy in patients with idiopathic pulmonary fibrosis.

Clinical Trials | 12/02/2026 | By News Bureau

VectorY Doses First Patient in Phase I/II PIONEER-ALS Trial of TDP-43 Targeting Therapy VTx-002

VectorY initiates clinical evaluation of VTx-002, a first-in-class vectorised antibody therapy targeting TDP-43 pathology in ALS, with first patient dosed at Mass General Brigham.

Clinical Trials | 11/02/2026 | By News Bureau |  162

Roche's Fenebrutinib Matches Ocrevus in Slowing Disability Progression in PPMS Phase III Trial

Phase III FENtrepid study shows oral BTK inhibitor fenebrutinib achieved non-inferiority to Ocrevus in primary progressive multiple sclerosis, reducing disability progression risk by 12 percent with consistent subgroup benefit.

Clinical Trials | 10/02/2026 | By News Bureau |  148

Late-breaking Data Highlight Positive Safety and Closure Rates for Abbott's New Stroke-prevention Device in non-Valvular AFib

Abbott has reported positive late-breaking data from the VERITAS Study showing its Amulet 360 Left Atrial Appendage Occluder met safety and effectiveness endpoints, supporting its potential to reduce stroke risk in patients with non-valvular atrial fibrillation.

Clinical Trials | 09/02/2026 | By News Bureau |  157

Delonix Bioworks Secures NMPA IND Clearance for MenB Vaccine Candidate DX-104

China grants IND approval for DX-104 after Australia CTN clearance, paving the way for Phase I trials of Delonix’s engineered Group B meningococcal vaccine.

Clinical Trials | 09/02/2026 | By News Bureau |  186

Roche's Fenebrutinib Becomes First Investigational Therapy in Over a Decade to Slow Disability Progression in PPMS

Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.

Clinical Trials | 09/02/2026 | By News Bureau |  131

Alvotech Announces Positive Results from Pharmacokinetic Study for Entyvio

Alvotech has reported positive top-line results from a pivotal pharmacokinetic study of AVT80, its proposed biosimilar to Entyvio. The study met all primary endpoints, demonstrating comparable pharmacokinetics, safety, tolerability and immunogenicity to the reference product in healthy adult participants.

Clinical Trials | 06/02/2026 | By News Bureau